SITC 2022

Presentations

Enfortumab Vedotin | Preclinical | Abstract #1187

Enfortumab vedotin induces immunogenic cell death, elicits antitumor immune memory, and shows enhanced preclinical activity in combination with immune checkpoint inhibitors